3 Undervalued Biotechnology Stocks for Friday, July 17
Discover the top 3 undervalued Biotechnology stocks for Friday, July 17 based on AAII’s Stock Grades.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company’s products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Commentary & Analysis
Why Vanda Pharmaceuticals Inc.’s (VNDA) Stock Is Up 5.15%
As of Wednesday, June 17, Vanda Pharmaceuticals Inc.’s VNDA share price has surged by 5.15%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Vanda Pharmaceuticals Inc.’s (VNDA) Stock Is Down 10.95%
As of Thursday, May 07, Vanda Pharmaceuticals Inc.’s VNDA share price has dipped by 10.95%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Vanda Pharmaceuticals Inc.’s (VNDA) Stock Is Down 11.16%
As of Thursday, May 07, Vanda Pharmaceuticals Inc.’s VNDA share price has dipped by 11.16%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Vanda Pharmaceuticals Inc.’s (VNDA) Stock Is Up 6.57%
As of Monday, May 04, Vanda Pharmaceuticals Inc.’s VNDA share price has surged by 6.57%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | VNDA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $306.7 | $252.6 | 32% |
|
| Shares Out (Mil) | 59.5 | 52.3 | 52% |
|
| Institutional Ownership | 94.5% | 92.1% | 65% |
|
| Float (Mil) | 53.8 | 40.2 | 49% |
|
| Beta | 0.65 | 0.95 | 38% |
|
| Avg Daily Volume (000s) | 797 | 455 | 66% |
|
| Price Change (52-week) |
9.2% | 52.9% | 53% |
|
| Growth | VNDA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (2.7%) | 13.6% | 11% |
|
| Net Income (5yr) | (62.9%) | (9.9%) | 5% |
|
| EPS (5yr) | (61.3%) | 16.0% | 2 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (24.9%) | (15.6%) | 25% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | VNDA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $218 | $38 | 33% |
|
| Net Income (TTM) (Mil) | ($240) | ($43) | 6% |
|
| EPS (TTM) | ($4.049) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($127) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($58) | $5 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $5 | 26% |
|
| Enterprise Value (Q1) (Mil) | $188 | $180 | 26% |
|
| Valuation | VNDA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.09 | 2.56 | 25% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | VNDA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 94.2% | 63.8% | 95% |
|
| Net Margin | (110.0%) | (67.3%) | 7% |
|
| ROA | (45.0%) | (49.8%) | 13% |
|
| ROE | (60.5%) | (55.5%) | 14% |
|
| Liabilities to Assets | 35.2% | 30.3% | 26% |
|
| F-Score | 3 | 3 | 19% |
|
Vanda Pharmaceuticals Inc. did not pass any screens on 7/31/2026.
